What Are Wall Street Analysts' Target Price for Kenvue Stock?

Summit, New Jersey-based Kenvue Inc. (KVUE) is the world's largest pure-play consumer health company. With a market cap of $37.4 billion, the company develops, manufactures, and markets a broad portfolio of over-the-counter (OTC) medicines, skincare, oral care, baby care, and other personal health products that are sold in more than 165 countries. 

KVUE stock has declined 11.7% over the past 52 weeks and has grown 14.5% on a YTD basis. In comparison, the S&P 500 Index ($SPX) has returned 16.3% over the past year and risen 8.5% in 2026.

More News from Barchart

• Nasdaq Futures Plunge as Chip Selloff Rages On, FOMC Meeting and Earnings on Tap

• Ahead of Microsoft Earnings, Here's What Barchart Data Says Comes Next for MSFT Stock

• Broadcom Leads 3 AI Stocks Quietly Raising Their Dividends, One by 161%

• Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now!

Narrowing the focus, KVUE has also underperformed the State Street Consumer Staples Select Sector SPDR ETF's (XLP) 7.9% rise over the past 52 weeks but has surpassed its 12.1% increase this year.

Over the past year, investors were concerned about Kenvue's sluggish sales growth, particularly in its Skin Health & Beauty segment, where brands like Neutrogena and Aveeno struggled amid weak consumer demand and heightened competition. The company also faced pressure from retailer inventory reductions, softer discretionary spending, and ongoing legal overhangs related to talc litigation inherited from its former parent, Johnson & Johnson (JNJ).

However, KVUE has rebounded in 2026 as investors grew more optimistic about the company's turnaround efforts. Management has focused on streamlining operations, improving margins through cost-cutting initiatives, refreshing key brands, and reviewing strategic options for underperforming skincare assets. 

For the current year ending in December, analysts expect KVUE's EPS to increase 7.4% year over year to $1.16. Moreover, the company has surpassed analysts' consensus estimates in each of the past four quarters.

Among the 13 analysts covering the stock, the consensus rating is a "Hold." That's based on one "Strong Buy" rating and 12 "Hold" ratings. 

This configuration is bearish than two months ago when the stock had two "Strong Buy" suggestions.  

On Jul. 21, Barclays raised its price target on Kenvue to $19 from $18 while maintaining an "Equal Weight" rating. The firm cited its second-quarter earnings preview, noting that investors remain selective in the consumer staples sector, favoring companies with reliable defensive characteristics and attractive valuations.